E
Engrail Therapeutics
Acquiring, developing and commercializing transformative medicines
About Engrail Therapeutics
Engrail Therapeutics is a clinical-stage pharmaceutical company dedicated to developing therapies for neurological and psychiatric disorders. The company's pipeline includes ENX-102, a GABAA positive allosteric modulator for generalized anxiety disorder, and ENX-104, a D2/D3 antagonist for major depressive disorder with anhedonia. Engrail's business model focuses on advancing its drug candidates through clinical trials to obtain regulatory approval and subsequent commercialization. The company targets the large and growing market for mental health treatments, a sector with significant unmet needs.
Engrail has secured substantial funding from venture capital firms, including a recent oversubscribed $157 million Series B financing round. This capital is being used to advance its clinical programs and expand its pipeline. The company's strategy involves building strong partnerships to support its research and development efforts. By focusing on precision neuroscience, Engrail aims to develop targeted therapies that offer improved efficacy and safety profiles compared to existing treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 70.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Feb 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2024 | $157M | $628M | Eight Roads Ventures · Pivotal Life Sciences · Forbion Capital Partners · Norwest Venture Partners | ↗ |
| SERIES AOther financing | Aug 2021 | $32M | $128M | Pivotal Life Sciences · Nan Fung Life Sciences Real Estate | — |
Growth signals
Latest recorded traffic for Engrail Therapeutics is 1.7K monthly website visits, up 13.3% over the last three months. Engrail Therapeutics's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Engrail Therapeutics in the San Diego ecosystem
The Engrail Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Pivotal Life Sciences
Nan Fung Life Sciences Real Estate
Forbion Capital Partners
Norwest Venture Partners
F-Prime
Eight Roads Ventures
Ysios Capital
Longwood Fund
RiverVest Venture Partners
Red Tree Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Engrail Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Engrail Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









